Plasmodium falciparum polypeptides and methods of using same

Details Plasmodium falciparum polypeptides and methods of using same Plasmodium falciparum polypeptides and methods of using same

2004-09-07

2010-06-15

Minnifield, N. M (Department: 1645)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023700, C536S023500, C435S069300, C435S320100, C435S069700, C800S278000

Reexamination Certificate

active

07737262

ABSTRACT:
Compositions and methods are provided for the induction of a protective immunize response in primates against a lethal challenge ofPlasmodium.

REFERENCES:
patent: 4745051 (1988-05-01), Smith et al.
patent: 5474914 (1995-12-01), Spaete
patent: 6270800 (2001-08-01), Speaker et al.
patent: 6420523 (2002-07-01), Chang et al.
patent: 6855316 (2005-02-01), Chang et al.
patent: 7037681 (2006-05-01), Chang et al.
patent: 7256281 (2007-08-01), Angov et al.
patent: 7285274 (2007-10-01), Chang et al.
patent: 2002/0058787 (2002-05-01), Strominger et al.
patent: 2002/0076403 (2002-06-01), Longacre-Andre et al.
patent: 2002/0194648 (2002-12-01), Chang et al.
patent: 2003/0100106 (2003-05-01), Chang et al.
patent: 2005/0037021 (2005-02-01), Chang et al.
patent: 2005/0095255 (2005-05-01), Chang et al.
patent: 2008/0075741 (2008-03-01), Angov et al.
patent: 0 329 257 (1989-08-01), None
patent: WO 97/30159 (1997-08-01), None
Bowie, et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science, 247, pp. 1306-1031 (1990).
Burghaus, et al., “Immunization ofAotus nancymaiwith Recombinant C Terminus ofPlasmodium falciparumMerozoite Surface Protein 1 in Liposomes and Alum Adjuvant Does Not Induce Protection against a Challenge Infection,”Infect.&Immun.64(9):3614-9 (1996).
Chang, et al., “Plasmodium falciparum: Gene Structure and Hydropathy Profile of the Major Merozoite Surface Antigen (gp195) of the Uganda-Palo Alto Isolate”Experimental Parasitology, 67: 1-11 (1988).
Chang, SP et al., “Generalized immunological recognition of the major merozoite surface antigen (gp195) ofPlasmodium falciparum,” Proc. Natl. Acad. Sci. USA86:6343-7 (1989).
Change, SP et al., “A Carboxyl-Terminal Fragment ofPlasmodium falciparumgp195 Expressed by the Recombinant Baculovirus Induces Antibodies that Completely Inhibit Parasite Growth,”J. Immunol.149(2):548-555 (1992).
Cheung et al. “Immunization with synthetic peptides of aPlasmodium falciparumsurface antigen induces antimerozoite antibodies,”Proc. Natl. Acad. Sci. USA83:8328 (1986).
Ellis, R.W., “New Technologies for Making Vaccines,” in Vaccines, Plotkin, S.A. and Mortimer, Jr. E.A., eds., W.B. Saunders Co., Philadelphia (1988), Ch. 29, pp. 568-575.
Hall et al. “Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria,”Nature, 311:379 (1984).
Herrera et al. “Conserved Polypeptides ofPlasmodium falciparumas Malaria Vaccine Candidates?”, Acta Leidensia, 60(1):107-110 (1991).
Herrera et al. “Immunization of Aotus monkeys withPlasmodium falciparumblood-stage recombinant proteins,”Proc. Natl. Acad. Sci. USA87:4017 (1990).
Holder et al., “A hybrid gene to express protein epitopes from both sporozoite and merozoite surface antigens ofPlasmodium falciparum,” Parasitology, 97:373-382 (1988).
Holder et al., “Immunization againstPlasmodium falciparumwith recombinant polypeptides produced inEscherichia coli,” Parastic Immunology, 10:607-617 (1988).
Holder et al., “Primary Structure of the Precursor to the three major surface antigens ofPlasmodium falciparummerozoite,”Nature, 317:270-273 (1985).
Holder et al., “Processing of the precursor to the major merozoite surface antigens ofPlasmodium falciparum.” Parasitology, 94:199-208 (1987).
Holder et at. “Immunization against blood-stage rodent malaria using purified parasite antigens,”Nature, 294:361 (1981).
Holder, A.A. et al., “Immunization againstPlasmodium falciparumwith recombinant polypeptides produced inEscherichia coli,” Parasite Immunology, 10(6):607-617 (1988).
Hui et al. “Serum from Pf195 protected Aotus Monkeys InhibitPlasmodium falciparumgrowth in Vitro,”Exp. Parasitol.64:519 (1987).
Hui, et al. “Induction of Antibodies to thePlasmodium falciparumMerozoite Surface Protein-1 (MSP1) by Cross-Priming with Heterologous MSPs”J. of Immunology, 153: 1195-1201 (1994).
Hui, et al., “Roles of Conserved and Allelic Regions of the Major Merozoite Surface Protein (gp195) in Immunity againstPlasmodium falciparum” Infection and Immunity, 60:1422-1433 (1992).
Knapp, 6. et al. “A histidin alanine rich recombinant antigen protects aotus monkeys fromP. falcipariuminfection,”Behrina Inst. Mitt.82:349-59 (1988).
Kumar. S et al.. “Immunogenicity and Efficacy inAotusMonkeys of Four RecombinantPlasmodium falciparumVaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1 ,”Infect.&Immun.68(4):2215-2223 (2000).
Lew et al. “A protective monoclonal antibody recognizes a linear epitope in the precursor to the major merozoite antigens ofPlasmodium chabaudi adami,” Proc. Natl. Acad. Sci. USA86:3768 (1989).
Locher, CP et at., “Plasmodium falciparum: gp195 Tripeptide Repeat-Specific Monoclonal Antibody Inhibits Parasite Growth in Vitro”Exp. Parisitol., 84:74-83 (1996).
Majarian et al. “Passive Immunization against Murine Malaria with an IgG3 Monoclonal Antibody,”J. Immunol.132:3131 (1984).
Murphy, V.F. et al., “Expression of hybrid malaria anitgens in insect cells and their engineering for correct folding and secretion.”Parasitology, 100 pt. 2:177-183 (1990).
Nishimura, T.A.T., “Distribution of MSP-1 Dimorphism in Papua New Guinea and the Importance of BVp42 Dimorphism in Antibody Recognition”, Master of Science in MicrobiologyThesis, University of Hawaii (Dec. 1999).
Odink K.G. et al., “Expression of cloned cDNA for a major surface antigen ofPlasmodium falciparummerozoite,”FEBS Lett., (1984) 108-12.
Patarroyo et al. “A synthetic vaccine protects humans against challenge with asexual blood stages ofPlasmodium falciparummalaria.”Nature, 332:158 (1988).
Patarroyo et al. “Induction of protective immunity against experimental infection with malaria using synthetic peptides,”Nature, 328:629 (1987).
Patarroyo et al. “Protective Synthetic Peptides against ExperimentalPlasmodium falciparum-induced Malaria,” Vaccines 87 (Brown, Chanock, Lerner. ed.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 117-124 (1987).
Perlaza et al., “Immunogenicity of fourPlasmodium falciparumpreerythrocytic antigens inAotus lemurinusmonkeys,”Infection and Immunity, 66(7):3423-3438 (1998).
Perrin et al. “Antimalarial immunity in Saimiri monkeys. Immunization with surface components of asexual blood stages.,”J. Exp. Med.160:441-451 (1984).
Rodriguez et al. “Studies in Owl Monkeys Leading to the Development of a Synthetic Vaccine Against the Asexual Blood Stages ofPlasmodium falciparum,” Am. J. Trop. Med. Hyg.43:339 (1990).
Ruebush et al.. “Immunization of Owl Monkeys with a Combination ofPlasmodium falciparumAsexual Blood-Stage Synthetic Peptide Antigens,”Am. J. Trop. Med. Hyg.43:355-366 (1990).
Saul et al., Second African Malaria Vaccine Testing Network Meeting, Accra, Ghana, Nov. 24-26, 1997.
Schreiber, et al., “A eukaryotic expression vector for the study of nuclear localization signals,”Gene, 150(2):411-412 (Dec. 1994).
Schwarz et al, “Structural Diversity of the Major Surface Antigen ofPlasmodium falciparumMerozoites,”Mol. Cell. Biol., 6(3):964-968 (1986).
Siddiqui et al. “Merozoite surface coat precursor protein completely protects Aotus monkeys againstPlasmodium falciparummalaria,” 1987.Proc. Natl. Acad. Sci. USA84:3014.
Smilek, D. et al., “A single amino acid change in myelin basic protein peptide confers the capacity to prevent rather than induce EAE”,Proc. Natl. Acad. Sci. USA88:9633-37 (1991).
Soltysik, “Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid rules in adjuvant function,”Vaccine1995, 13(15):1403-1410.
Stowers, AW et al., “A rec

Affiliated with

Also associated with

Rating

Plasmodium falciparum polypeptides and methods of using same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Plasmodium falciparum polypeptides and methods of using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasmodium falciparum polypeptides and methods of using same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4205058